Alliances and collaborations are at the heart of the Novartis Malaria Initiative, one of the healthcare industry's largest access-to-medicine programs.
Since 2001, working with a range of organizations, we have provided more than 750 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries.
In 2015, deliveries of our child-friendly formulation hit the 300 million mark since launch in 2009. Never before have so many pediatric treatments been distributed in such a short time frame for children suffering from malaria.
We are proud of the remarkable public heath milestones these efforts and collaborations have helped to achieve.